Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

User Fees For FY 2017 Make Sponsors Happy, Manufacturers Sad

Executive Summary

Several facility fees will increase next year as application fees drop.

You may also be interested in...



GDUFA Negotiations Shift To 'Tiered' Fee Models

Finance subgroup talks about new structure for generic drug user fee program that could mean bigger firms would pay more.

PDUFA Fees Forced Down For FY 2017 Due To Refund Provision

Final year of this user fee cycle will include 14% discount, but agency says it is ready for revenue reduction.

ANDA User Fees Offer Sponsor Relief, But More Facility Pain

Final GDUFA I application fees decrease amid expected boost in submissions, while facility fees will increase for the fourth time in five years.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB001942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel